The facts on 1,2,3-Trichloropropane

The facts on 1,2,3-Trichloropropane

Estimates of current numbers of exposed workers to 1,2,3-Trichloropropane (1,2,3-TPC) in the EU are not available. Inhalation is considered as the primary route of exposure although workers can be exposed through dermal contact as well.

1,2,3-TPC is classified as Carcinogenic Category 1B (according to CLP Regulation), which means it is presumed to have carcinogenic potential for humans, based on animal evidence.

There is no human data on whether 1,2,3-TCP causes cancer in humans available. Studies in animals show that prolonged exposure to this substance may cause tumours at multiple sites, such as in the oral cavity and forestomach.

Where risks occur

The primary use of 1,2,3-TPC is as a monomer in the manufacture of polymers or as an intermediate in the production of other substances (pesticides, 2,3-dichloropropene, polysulfides and hexafluoropropylene). 1,2,3-TCP may remain as an impurity in some of these chemicals. 1,2,3-TCP is produced in significant quantities as a by-product during the manufacture of epichlorohydrin when chlorine is added to allyl chloride. This process takes place in closed systems.
In general, workplace exposure appears to be limited due to handling under strictly controlled conditions. The main activity where exposure is possible is during manual maintenance or cleaning activities.

More about the substance

In its pure form, 1,2,3-TPC is a colourless to yellow liquid with limited solubility in water, a strong chloroform-like odour, moderate volatility, and high flammability. It’s a man-made chemical, present in the environment as a result of anthropogenic activity.
An EU-wide binding occupational exposure limit value is currently under preparation.

Hazards that may occur

Acute toxicity data in humans are limited to a small number of case reports, which describe primarily liver and neurological effects following high, but generally not well‑quantified, oral or inhalation exposure. The most relevant health effect of chronic exposure to 1,2,3‑TCP is carcinogenicity. No data are available in humans. In experimental animals, 1,2,3‑TCP induces tumours at multiple sites and with high incidence in both mice and rats. As the metabolism of 1,2,3‑TCP is qualitatively similar in human and rodent microsomes, it is considered likely to be carcinogenic to humans.

What you can do

At the workplace, the most effective way to prevent exposure is by substitution of 1,2,3-TCP. Where substitution is not possible and use of 1,2,3-TCP cannot be avoided, measures to reduce exposure must be taken.

The most effective way to avoid exposure to 1,2,3-TCP is to develop and use closed systems. Where this is not possible, technical measures such as effective local exhaust ventilation, supplemented by good general workplace ventilation and regular checks of their effectiveness, should be implemented to ensure that exposure is minimised as much as technically possible.

Implement regular exposure assessments to check if your protective measures in place are effective or whether further actions need to be taken. Workers need to be aware of the effects of exposure and should be trained regularly on the control measures necessary for working safely with 1,2,3-TCP to prevent exposure. Involving an occupational physician is recommended.

Ensure that workers have adequate personal protective equipment, such as protective clothing and gloves, if necessary. Personal protective equipment should not be used as the only preventive measure. As many of the above technical and organisational measures as possible must have been implemented beforehand. Make sure the right personal protective equipment is used, like eyes and face protection, gloves, protective clothing and breathing protection. In addition, when selecting equipment, the anatomy of the workers who will be using it must be taken into account and, in the case of respiratory protective equipment based on facial adjustment, it is highly recommended that a fit test be carried out on each person. Additionally, all workers should be instructed to wash their hands properly before taking a break or entering another area, and to wash themselves and change their clothes at the end of each shift.

Personal protective equipment should only be used as a last resort and only considered temporarily, after the possible technical solutions have been exhausted.

References: ECHA

Limit values

EU
A BOELV is under preparation.

Please note that due to transitional periods in the Directive, national OELs might deviate from the BOELV. The overview on national OELs is updated in the 4th quarter every year and may also be the reason for deviation.

 Austria

300mg/m³ (TWA), 1500mg/m³ (STEL)
 Belgium
0,03mg/m³ (TWA)
Bulgaria
EU directive
Croatia
EU directive
Czech Republic
EU directive
Cyprus
EU directive
Denmark
0,6mg/m³ (TWA), 1,2mg/m³ (STEL)
Estonia
EU directive
Finland
18mg/m³ (TWA)
France
EU directive
Germany
EU directive
Greece
EU directive
Hungary
EU directive
Iceland
EU directive
Ireland
0,005ppm (TWA)
Italy
EU directive
Latvia
2mg/m³ (TWA)
Lithuania
EU directive
Luxembourg
EU directive
Malta
EU directive
Netherlands
0,00108mg/m³ (TWA)
North Macedonia
EU directive
Norway
60mg/m³ (TWA)
Poland
7mg/m³ (TWA)
Portugal
EU directive
Romania
EU directive
Serbia
EU directive
Slovakia
EU directive
 Slovenia
EU directive
Spain
61mg/m³ (TWA)
Sweden
EU directive
Turkey
EU directive

References: cancer.gov, EFSA, IARC, EC, NIOSH, OSHA, CAREX

Please be aware that for this carcinogen you need to be more cautious when determining potential skin contact and how to regard dermal exposure in your risk reduction strategy.
ECHA registration
CAS number 96-18-4
EC number 202-486-1
Annex VI of CLP 1B
Number of registrations 5
Tonnage band registred Registered for intermediate use only

The European Chemicals Agency (ECHA) works for the safe use of chemicals. It implements the EU’s groundbreaking chemicals legislation, benefiting human health, the environment and innovation and competitiveness in Europe.

GESTIS Database

The data pool may be used for the purpose of occupational health and safety or to obtain information on the hazards posed by chemical substances.

General facts

Facts about cancer-causing agents:

  • The direct costs of carcinogen exposure at work across Europe are estimated at 2.4 billion Euros per year.
  • Every year, about 120.000 persons get cancer from exposure to carcinogens at work
  • Annually more than 100.000 people die because of work-related cancer.

Table of contents

Sign up for our newsletter to become part of our community. Or follow us on LinkedIn and join the conversation!